Patient-Focused Drug Development: Methods to Identify What Is Important to Patients

On 25 February 2022 the FDA published the final guidance for Industry, FDA staff and other stakeholders.

This guidance (Guidance 2) is the second in a series of four methodological patient-focused drug development (PFDD) guidance documents that FDA is developing to describe in a stepwise manner how stakeholders (patients, researchers, medical product developers and others) can collect and submit patient experience data and other relevant information from patients and caregivers to be used for medical product development and regulatory decision-making.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /